Table 2.

Scoring System for the UCSF-CAPRA Risk Score Prediction Tool With Corresponding 5-Year Recurrence-Free Survival Estimates According to Score

I. PSA		II. Gleason Score
2.1–6.0 = 0
6.1–10 = 1		1–3/1–3 = 0
10.1–20 = 2		1–3/4–5 = 1
20.1–30 = 3		4–5/1–5 = 3
>30 = 4
	III. Clinical T Stage
	T1/T2 = 0
	T3a = 1
IV. % Positive Biopsies		V. Age
<34% = 0		<50 years = 0
≧34% = 1		≧50 years = 1
UCSF-CAPRA Score		5-Year Recurrence-Free Survival Estimate (95% CI)
0–1 points		85% (73–92)
2 points		81% (69–89)
3 points		66% (54–76)
4 points		59% (40–74)
5 points		60% (37–77)
6 points		34% (12–57)
≧7 points		8% (0–28)

PSA, prostate specific antigen; UCSF-CAPRA, University of California, San Francisco-Cancer of the Prostate Risk Assessment.

A point value from each of the 5 categories is summed to calculate the CAPRA score. Scores range from 0–10.

Recurrence defined as PSA ≧ 0.2 ng/mL on 2 consecutive postprostatectomy measurements or a 2nd cancer treatment > 6 months after prostatectomy.

Adapted with permission from The Journal of Urology, Vol 173, Cooperberg MR et al., “The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy,” pp. 1938–1942, Copyright 2005, with permission from the American Urological Association.¹⁴